Ironically the title of the CDC reports is COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021.
Talk about Orwellian newspeak.
As of July 30, 2021, only the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine is authorized for adolescents aged 12–17 years. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech vaccine for use in persons aged ≥16 years on December 11, 2020.
The EUA was expanded to include adolescents aged 12–15 years on May 10, 2021, based on results from a Phase 3 clinical trial
Approximately 129,000 U.S. adolescents aged 12–17 years enrolled in v-safe after Pfizer-BioNTech vaccination. (v-safe is a voluntary smartphone-based active safety surveillance system to monitor adverse events after COVID-19 vaccination.) v-safe complied both local (63.4%) and systemic (48.9%) reactions.
If a report indicated medical attention was sought, VAERS staff members contacted the reporter and encouraged completion of a VAERS report, if indicated.
But not all data from December 16, 2020, is included. Because…
VAERS reports for adolescents aged 12–15 years were excluded if vaccination occurred before Emergency Use Authorization age expansion on May 10, 2021.
The VAERS data in this report, which includes deaths, is only for May 10, 2021 – July 16, 2021. Three months! Not from December to July.
Five months of data were excluded!
And then FDA further trimmed down the data by…
FDA used empirical Bayesian data mining to monitor for disproportional reporting of adverse events by vaccine among VAERS reports for persons aged 12–17 years.
VAERS Data
VAERS received and processed 9,246 reports of adverse events for adolescents aged 12–17 years who received the Pfizer-BioNTech vaccine from December 14, 2020–July 16, 2021.
Overall, 8,383 (90.7%) VAERS reports were for non-serious events, and 863 (9.3%) for serious events, including death;
609 (70.6%) reports of serious events were among males, and the median age was 15 years.
The most commonly reported conditions and diagnostic findings among serious events were:
- Chest pain (56.4%),
- Increased troponin levels (41.7%),
- Myocarditis (40.3%),
- Increased c-reactive protein (30.6%),
- negative SARS-CoV-2 test results (29.4%) (Table 2); these findings are consistent with a diagnosis of myocarditis. Myocarditis was listed among 4.3% (397) of all VAERS reports.
Deaths
- Four were aged 12–15 years
- 10 were aged 16–17 years.
Causes of deaths
- Pulmonary embolism(two)
- Suicide (two)
- Intracranial hemorrhage (two)
- Heart failure (one)
- Hemophagocytic lymphohistiocytosis
- Disseminated Mycobacterium chelonae infection (one)
- Unknown or pending further records (six).
All of the above causes of death except for suicide are rare for this age group.
Most people who read the report will only pay attention to the summary and not read the whole report.
That summary partly says,
What are the implications for public health practice?
Mild local and systemic reactions are common among adolescents following Pfizer-BioNTech vaccine, and serious adverse events are rare. The Advisory Committee on Immunization Practices conducted a risk-benefit assessment and continues to recommend the Pfizer-BioNTech COVID-19 vaccine for all persons aged ≥12 years.
CDC continues to recommend the Pfizer vaccine even though 863 (9.3%) serious events, including death in three months, have been reported.
I remember a video of a teenager who talked about his myocarditis from the COVID-19 vaccine, and I paraphrase, “The myocarditis is not that rare from where I am.”
Before you consider the jab, read this: Asymptomatic or mild symptomatic COVID-19 elicits effective and long-lasting antibody responses in children and adolescents.
Putting a face on the myocarditis
- Oregon teen who said his heart hurt was hospitalized with myocarditis after COVID-19 vaccination
- Washington Co. teen’s parents warning about myocarditis, rare condition possibly linked to COVID-19
- Teen Suffers Heart Attack Day After Pfizer COVID-19 Vaccine Jab
- Mom of Conn. Teen Speaks After Son Suffers Heart Condition Days After COVID-19 Vaccine
- Kenmore teen develops myocarditis after 2nd vaccine shot; CDC investigating possible rare side effect
- Teen boy dies a few days after receiving second COVID vaccine shot
What is the risk of dying from COVID-19 among teenagers?
- Age 10-14 years old 0.001
- Age 15-19 years old 0.003
You can read more about it here: What is Your Risk of Dying from COVID-19 for your Age Group?
Knowledge about Covid-19 is rapidly evolving. Information may update as new studies are made. Stay current by subscribing. Feel free to share and like.
Don’t Get Sick!
Pfizer Related:
- Durable Immunity from Pfizer COVID-19 Vaccine Lasts only Six Months
- Who develops a better Immunity against SARS-CoV-2? The vaccinated or the previously infected?
- C.D.C. reports on the Danger of the Pfizer COVID-19 vaccine to adolescents aged 12-17 years
You may also like:
- The Updated List of COVID-19 Articles
- The Whole English translation of the Spanish study showing 99% Graphene Oxide in the Pfizer COVID-19 Vaccine
- Risk (Death) Benefit (Life-Saving) Ratio of the COVID-19 Vaccines
- Cerebral Thrombosis after the Pfizer Covid-19 Vaccine
- How infectious are asymptomatic COVID-19 cases?
- Know the Absolute Risk Reduction of the COVID-19 Vaccines!
- Myocarditis and the COVID vaccine
- What is Your Risk of Dying from COVID-19 for your Age Group?
- The study shows a 10 fold risk of developing blood clots after the COVID vaccine.
- SARS-CoV-2 RNA can Change Human Genes.
- You got the COVID shot and found that others developed blood clots. Now what?
- Blood Clot formation after COVID Vaccination
- Deadly Autoimmune Antibodies
- COVID-19, Autoimmunity, and Vaccination Part 3
As an Amazon Associate, I earn from qualifying purchases.
© 2018 – 2021 Asclepiades Medicine, LLC All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment.